Research on the health-related quality of life (HrQoL) impact of short stature and its treatment in children and adolescents has developed recently. Based on a PubMed literature search, studies addressing this issue were identified and considerable methodological problems mainly related to the HrQoL instruments used and conflicting results are discussed in this mini review. Additionally, this mini review identifies a need for further research and indicates potential directions.

Keywords:
Growth hormone deficiency, Idiopathic short stature, Quality of life
1.
Lifshitz F, Cervantes CD: Short stature; in Lifshitz F (ed): Pediatric Endocrinology, ed 3. New York, Dekker, 1996, pp 1–18.
2.
Lantos J, Siegler M, Cuttler L: Ethical issues in growth hormone therapy. JAMA 1989;261:1020–1024.
3.
Lee MM: Idiopathic short stature. N Engl J Med 2006;354:2576–2582.
4.
Finkelstein BS, Imperiale TF, Speroff T, Marrero U, Radcliffe DJ, Cuttler L: Effect of growth hormone therapy on height in children with idiopathic short stature: a meta-analysis. Arch Pediatr Adolesc Med 2002;156:230–240.
5.
Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL, Chernausek SD, Savage MO, Wit JM; on behalf of the 2007 ISS Consensus Workshop participants: Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. J Clin Endocrinol Metab 2008;93:4210–4217.
6.
Miller BS, Zimmerman D: Idiopathic short stature in children. Pediatr Ann 2004;33:177–181.
7.
Bryant J, Baxter L, Cave C, Milne R: Recombinant growth hormone for idiopathic short stature in children and adolescents. Cochrane Database Syst Rev 2007;3:CD004440.
8.
Sandberg DE: Health-related quality of life as a primary endpoint for growth hormone therapy. Horm Res 2006;65:250–252.
9.
Wheeler PG, Bresnahan K, Shephard BA, Lau J, Balk EM: Short stature and functional impairment. Arch Pediatr Adolesc Med 2004;158:236–243.
10.
Kranzler JH, Rosenbloom A, Proctor B, Diamon FB, Watson M: Is short stature a handicap? A comparison of the psychosocial functioning of referred and nonreferred children with normal short stature and with normal stature. J Pediatr 2000;136:96–102.
11.
Chaplin JE, Dahlgren J, Kriström B, Albertsson-Wikland A: Psychological importance to the child of growth hormone replacement; in Nyberg FJ (ed): The Somatotrophic Axis in Brain Function. Amsterdam, Elsevier, 2006, pp 249–266.
12.
Voss LD, Mulligan J: Bullying in school: are short pupils at risk? Questionnaire study in a cohort. BMJ 2000;320:612–613.
13.
Sandberg DE, Colsman M: Growth hormone treatment of short stature: status of the quality of life rationale. Horm Res 2005;63:275–283.
14.
Sandberg DE, MacGillivray MH, Clopper RR, Fung C, LeRoux L, Alliger DE: Quality of life among formerly treated childhood-onset growth hormone-deficient adults: a comparison with unaffected siblings. J Clin Endocrinol Metab 1998;83:1134–1142.
15.
Zimet GD, Cutler M, Litvene M, Dahms W, Owens R, Cuttler L: Psychological adjustment of children evaluated for short stature: a preliminary report. J Dev Behav Pediatr 1995;16:264–270.
16.
Sandberg DE: Quality of life and self-esteem in children treated for idiopathic short stature. J Pediatr 2003;143:691.
17.
Visser-van Balen H, Sinnema G, Geenen R: Growing up with idiopathic short stature: psychosocial development and hormone treatment: a critical review. Arch Dis Child 2006;91:433–439.
18.
Sandberg DE, Colsman MD, Voss LD: Short Stature and Quality of Life: A Review of Assumptions and Evidence, Pediatric Endocrinology: Mechanisms, Manifestations, and Management. Philadelphia, Lippincourt, Williams & Wilkins, 2004, pp 191–202.
19.
Noeker M, Haverkamp F: Adjustment in conditions with short stature: a conceptual framework. J Pediatr Endocrinol Metab 2000;13:1585–1594.
20.
Erling A: Why do some children of short stature develop psychologically well while others have problems? Eur J Endocrinol 2004;151:35–39.
21.
Radcliffe DJ, Pliskin JS, Silvers JB, Cuttler L: Growth hormone therapy and quality of life in adults and children. Pharmacoeconomics 2004;22:499–524.
22.
Leiberman E, Pilpel D, Carel CA, Levi E, Zadik Z: Coping and satisfaction with growth hormone treatment among short-stature children. Horm Res 1993;40:128–135.
23.
Pilpel D, Leiberman E, Zadik Z, Carel CA: Effect of growth hormone treatment on quality of life of short-stature children. Horm Res 1995;44:1–5.
24.
Sandberg DE, Brook AE, Campos SP: Short stature: a psychosocial burden requiring growth hormone therapy? Pediatrics 1994;94:832–840.
25.
Cramer JA, Claude Simeoni M, Auquier P, Robitail S, Brasseur P, Beresniak A: Brief report: a quality of life instrument for adolescents with growth disorders. J Adolesc 2005;28:595–600.
26.
Norrby U, Nordholm L, Andersson-Gäre B, Fasth A: Health-related quality of life in children diagnosed with asthma, diabetes, juvenile chronic arthritis or short stature. Acta Paediatr 2006;95:450–456.
27.
Ross JL, Sandberg DE, Rose SR, Leschek EW, Baron J, Chipman JJ, Cassorla FG, Quigley CA, Crowe BJ, Roberts K, Culter GH: Psychological adaptation in children with idiopathic short stature treated with growth hormone or placebo. J Clin Endocrinol Metab 2004;89:4873–4878.
28.
Theunissen NC, Kamp GA, Koopman HM, Zwinderman KA, Vogels T, Wit JM: Quality of life and self-esteem in children treated for idiopathic short stature. J Pediatr 2002;140:507–515.
29.
Verrips GH, Vogels AGC, Koopman HM, Theunissen NCM, Kamphuis RP, Wit HM, Verloove Vanhorick SP: Measuring health-related quality of life in a child population. Eur J Public Health 1999;9:188–193.
30.
Theunissen NC, Kamp GA, Koopman HM, Zwinderman KA, Vogels T, Wit JM: Quality of life and self-esteem in children treated for idiopathic short stature. J Pediatr 2002;140:507–515.
31.
Sheppard L, Eiser C, Davies HA, Carney S, Clarke SA, Urquart T, Ryder MJ, Stoner A, Wright NP, Butler G: The effects of growth hormone treatment on health-related quality of life in children. Horm Res 2006;65:243–249.
32.
Mauras N, Pescovitz OH, Allada V, Messig M, Wajnrajch MP, Lippe B; Transition Study Group: Limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: a phase III multicenter, double-blind, randomized two-year trial. J Clin Endocrinol Metab 2005;90:3946–3955.
33.
Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). Conceptual framework and item selection. Med Care 1992;30:473–483.
34.
McKenna SP, Doward LC, Alonso J, Kohlmann T, Niero M, Prieto L, Wiren L: The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Qual Life Res 1999;8:373–383.
35.
Attanasio AF, Shavrikova EP, Blum WF, Shalet SM: Quality of life in childhood onset growth hormone-deficient patients in the transition phase from childhood to adulthood. J Clin Endocrinol Metab 2005;90:4525–4529.
36.
Herschbach P, Henrich G, Strasburger CJ, Feldmeier H, Marin F, Attanasio AM, Blum WF: Development and psychometric properties of a disease-specific quality of life questionnaire for adult patients with growth hormone deficiency. Eur J Endocrinol 2001;145:255–265.
37.
Lagrou K, Xhrouet-Heinrichs D, Massa G, Vandeweghe M, Bourguignon JP, De Schepper J, de Zegher F, Ernould C, Heinrichs C, Malvaux P, Craen M: Quality of life and retrospective perception of the effect of growth hormone treatment in adult patients with childhood growth hormone deficiency. J Pediatr Endocrinol Metab 2001;14(suppl 5):1249–1260.
38.
Sandberg DE, Ognibene TC, Brook AE, Barrick C, Shine B, Grundher W: Academic outcomes among children and adolescents receiving growth hormone therapy. Child Health Care 1998;27:265–282.
39.
Gilmour J, Skuse D: Short stature – the role of intelligence in psychosocial adjustment. Arch Dis Child 1996;75:25–31.
40.
Sandberg DE, Bukowski WM, Fung CM, Noll RB: Height and social adjustment; are extremes a cause for concern and action? Pediatrics 2004;114:744–750.
41.
Perrin JM: Health services research for children with disabilities. Milbank Q 2002;80:303–324.
42.
Clarke S, Eiser C: The measurement of health-related quality of life (QoL) in paediatric clinical trials: a systematic review. Health Qual Life Outcomes 2004;2:66.
43.
Petersen C, Schmidt S, Bullinger M; DISABKIDS Group: Coping with a chronic pediatric health condition and health-related quality of life. Eur Psychol 2006;11:50–56.
44.
Achenbach TM: Program Manual for the Child Behavior Checklist and Revised Child Behavior/4–18 Profile. Burlington, Queen City Printers, 1991.
45.
Simeoni MC, Auquier P, Antoniotti S, Sapin C, Marco JLS: Validation of a French health-related quality of life instrument for adolescents: the VSP-A. Qual Life Res 2000;9:393–403.
46.
Landgraf JM, Abetz L, Ware JE: Child Health Questionnaire: A User’s Manual. Boston, The Health Institute, New England Medical Center, 1996.
47.
Bannink EM, van Pareren YK, Theunissen NC, Raat H, Mulder PG, Hokken-Koelega AC: Quality of life in adolescents born small for gestational age: does growth hormone make a difference? Horm Res 2005;64:166–174.
48.
Koopman HM, Theunissen NCM, Vogels AGC, Zwinderman AH, Verloove-Vanhorick SP, Wit JM: Health-related quality of life of children with a chronic illness: parent versus child report. Gedrag Gezondheit 1999;27:118–125.
49.
Harter S: Manual for the Self-Perception Profile for Children. Denver, University of Denver, 1985.
50.
Varni JW, Seid M, Rode CA: The PedsQLTM: measurement model for the pediatric quality of life inventory. Med Care 1999;37:126–139.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.